2012 CareLigo was founded by Fredrik Westman and Andreas Blomqvist, who together bring 20 years of the medtech industry to the table. The company was founde on a vision of making it easy for the patient to assume control over his/her situation. By putting the patient first, and boosting self-care behavior, the patient will be empowered, experience a higher quality of life, while at the same time generating substantiual savings for the health care system.
Most of 2012 was spent on product development and market analyses. Towards the end of the year, CareLigo got new owners and a new board of directors was formed.
2013 The product, now known as OPTILOGG, was CE-marked and got the regulatory approval for the European market. The first clinical trial was conducted and successfully closed by December of that year. We were now geared to move to market launch.
2014 The first publication of the findings from the study saw the light of day, and our first customer contract was signed. New capital was raised, a new board was formed and new employees were hired.
2015 The patent for OPTILOGG was issued and new customers were found. Another randomized controlled trial was carried out, this time in the primary care setting. This year the first peer reviewed article was published in a journal.
2016 OPTILOGG is used by one or more health care providers in ten counties throughout Sweden and by Q4, CareLigo was profitable. New clinical findings were presented at scientific congresses.
2017 The first public procurement of OPTILOGG by a county council took place. We hope more are under way!